Patient Selection for Efficacious Mandibular Advancement Device Therapy in Obstructive Sleep Apnea: An Institutional Outcomes Analysis
Annals of Otology, Rhinology & Laryngology · 2025-08 · 134 (8) · 575-582
DOI: 10.1177/00034894251334725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Otology, Rhinology & Laryngology, online erschienen am 26.04.2025. Verfasst von Nainika Nanda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Mandibular Advancement, Patient Selection. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Introduction
Mandibular advancement devices (MADs) are a treatment option for obstructive sleep apnea/hypopnea syndrome (OSAHS); however, the ideal patient selection criteria continue to be refined.
Objectives
To determine the overall efficacy of a custom titratable MAD in treating a subset of OSAHS patients. A secondary objective was to determine predictive factors affecting treatment outcome for MAD therapy.
Methods
Retrospective analysis of a single otolaryngologist’s (DCU) experience in 86 patients with Friedman Stages 2 to 4 treated with a MAD (Thornton Adjustable Positioner) at an academic medical center.
Results
Therapeutic success as measured by type 3 home apnea test (HSAT) before and after proper MAD titration was defined as a 50% reduction in initial AHI or reduction of AHI to a mild severity below 15 events/hour. The 50% AHI reduction rate after MAD titration was 64% and the overall success rate inclusive of patients with reduction below 15 events/hour was 72.1%. MAD therapy significantly reduced the mean AHI (−10.4 ± 12.6), P < .001) and improved the minimum oxygen saturation (1.88 ± 5.79, P = .003). Significant reduction of OSAHS severity was seen across all treatment groups regardless of initial OSAHS severity: mild (55.9%), moderate (85%), severe (75%; P < .001 for all 3 groups). High BMI, advanced age, concentric velopharyngeal collapse pattern, prior pharyngeal surgery, and male sex were not statistically significant predictors of ineffectiveness.
Conclusions
MAD therapy for OSAHS in patients with Friedman Stages 2 to 4 is an effective treatment in 72% of cases and should be considered as an initial treatment option within this subset of patients, inclusive of those with initially severe, moderate, and mild OSAHS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of California Los Angeles, CA, USA.
ORCID-Profile: Nainika Nanda, Aaron Robertson, David C Upton
Zitieren
APA
Nanda, N., Robertson, A., & Upton, D. C. (2025). Patient Selection for Efficacious Mandibular Advancement Device Therapy in Obstructive Sleep Apnea: An Institutional Outcomes Analysis. Annals of Otology, Rhinology & Laryngology, 134(8), 575-582. https://doi.org/10.1177/00034894251334725
Vancouver
Nanda N, Robertson A, Upton DC. Patient Selection for Efficacious Mandibular Advancement Device Therapy in Obstructive Sleep Apnea: An Institutional Outcomes Analysis. Annals of Otology, Rhinology & Laryngology. 2025;134(8):575-582. doi:10.1177/00034894251334725
BibTeX
@article{Nanda2025,
author = {Nanda, Nainika and Robertson, Aaron and Upton, David C},
title = {Patient Selection for Efficacious Mandibular Advancement Device Therapy in Obstructive Sleep Apnea: An Institutional Outcomes Analysis},
journal = {Annals of Otology, Rhinology & Laryngology},
year = {2025},
volume = {134},
number = {8},
pages = {575--582},
doi = {10.1177/00034894251334725}
}
EUVIMED